Role of MIF and CD74 in the pathogenesis of emphysema
MIF和CD74在肺气肿发病机制中的作用
基本信息
- 批准号:10543511
- 负责人:
- 金额:$ 68.48万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-01-01 至 2025-12-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAgonistAllelesApoptosisAttenuatedBiologyCause of DeathCell AgingCellsChronicChronic Obstructive Pulmonary DiseaseCigarette smoke-induced emphysemaCytoprotectionDNA DamageDataDevelopmentDiseaseDisease ProgressionEndothelial CellsEndotheliumFlow CytometryGeneticGenetic PolymorphismGenetic studyGoalsHistologyHomeostasisHumanImageImmuneLoxP-flanked alleleLungLung diseasesMAPK3 geneMacrophageMediatingMethodsMigration Inhibitory FactorMolecularMouse StrainsMusOxidative StressOxidative Stress InductionPathogenesisPathologicPathway interactionsPatientsPredispositionProteinsPulmonary EmphysemaReporterResearch PersonnelRisk FactorsRoleSeveritiesSeverity of illnessSignal PathwaySignal TransductionSliceSmokerStudy modelsTestingTherapeuticTissuesTranslatingTreatment EfficacyUnited StatesVisualizationWorkX-Ray Computed Tomographycell typecigarette smokecigarette smoke-inducedcytokineeffective therapyexposure to cigarette smokegain of functionimprovedloss of functionmigrationmodifiable riskmouse modelnew therapeutic targetnoveloxidative DNA damagepharmacologicpromoterprotective effectreceptorresilienceresponsesenescencesmall moleculestress reduction
项目摘要
PROJECT SUMMARY
Emphysema is a common pathologic manifestation of Chronic Obstructive Pulmonary Disease (COPD), the
fourth leading cause of death in the United States. The most important modifiable risk factor for emphysema is
chronic exposure to cigarette smoke (CS). Yet, not all smokers develop emphysema and, therefore, cellular
responses to CS are important mechanisms underlying disease progression. Our long-term goal is to define
the cellular responses to CS and oxidative stress that protect the lung from emphysema. We have identified a
cytoprotective role for the innate immune cytokine Macrophage Migration Inhibitory (MIF). MIF decreases
oxidative stress and consequences of oxidative stress (e.g. cellular senescence and apoptosis) in lung
endothelial cells, and mice with a genetic deletion of Mif are susceptible to emphysema. MIF is secreted in
response to CS, but, paradoxically, MIF is decreased in patients with severe COPD. Targeting MIF, or its
downstream pathways, may be therapeutic. However, MIF is a pleiotropic molecule with broad regulatory effects.
To translate MIF biology into therapy, it will be essential to dissect out its cytoprotective pathways. Our goal for
this proposal is to determine the mechanisms through which MIF antagonizes the development of emphysema.
Our preliminary data suggests MIF mediates its protective effects through its receptor CD74. Our hypothesis is
MIF protects against the development of emphysema by mitigating CS-mediated endothelial senescence in a
CD74 dependent manner. In Aim 1, we will define the mechanism through which the MIF-CD74 interaction
reduces endothelial senescence. In Aim 2, we will determine the role of endothelial CD74 in regulating
susceptibility to emphysema. In Aim 3, we will determine the therapeutic potential of targeting MIF-CD74
interactions in emphysema. Completion of these aims will significantly advance our understanding of the
pathogenesis of emphysema and may identify precision-based approaches based on MIF biology for treating
patients with emphysema.
项目摘要
肺气肿是慢性阻塞性肺疾病(COPD)的常见病理表现,
美国第四大死亡原因。肺气肿最重要的可修改风险因素是
长期暴露于香烟烟雾(CS)。但是,并非所有吸烟者都会发展出肺气肿,因此,细胞
对CS的反应是疾病进展的重要机制。我们的长期目标是定义
细胞对CS的反应和保护肺部免受肺气肿的氧化应激。我们已经确定了
先天免疫细胞因子巨噬细胞迁移抑制(MIF)的细胞保护作用。 MIF减少
氧化应激的氧化应激和后果(例如,肺细胞衰老和凋亡)
内皮细胞和具有MIF遗传缺失的小鼠容易受到肺气肿的影响。米夫被分泌
对CS的反应,但矛盾的是,严重COPD患者的MIF减少。针对MIF或ITS
下游途径可能是治疗性的。但是,MIF是一种具有广泛调节作用的多效分子。
为了将MIF生物学转化为治疗,必须剖析其细胞保护途径。我们的目标
该建议是确定MIF拮抗肺气肿发展的机制。
我们的初步数据表明,MIF通过其受体CD74介导了其保护作用。我们的假设是
MIF通过缓解CS介导的内皮衰老A在A中预防肺气肿的发展
CD74依赖方式。在AIM 1中,我们将定义MIF-CD74相互作用的机制
减少内皮衰老。在AIM 2中,我们将确定内皮CD74在调节中的作用
对肺气肿的敏感性。在AIM 3中,我们将确定针对MIF-CD74的治疗潜力
肺气肿的相互作用。这些目标的完成将大大提高我们对
肺气肿的发病机理,并可能基于MIF生物学来识别基于精确的方法用于治疗
肺气肿的患者。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Maor Sauler其他文献
Maor Sauler的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Maor Sauler', 18)}}的其他基金
Role of MIF and CD74 in the pathogenesis of emphysema
MIF和CD74在肺气肿发病机制中的作用
- 批准号:
10322669 - 财政年份:2021
- 资助金额:
$ 68.48万 - 项目类别:
相似国自然基金
内源激动剂ArA靶向TMEM175蛋白缓解帕金森病症的分子机制研究
- 批准号:32300565
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
Adrb2激动剂在改善呼吸机相关性膈肌功能障碍中的作用与机制研究
- 批准号:82372196
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
新型IL2Rβγ激动剂逐级控释联合放疗对抗三阴性乳腺癌的作用及机制研究
- 批准号:82303819
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于OSMAC-GNPS分析策略的蚂蚱内生真菌Aspergillus sp.中新颖泛PPAR激动剂的发现及治疗NASH研究
- 批准号:82304340
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
探究FSP1激动剂在治疗肾缺血再灌注损伤中的分子机理与应用
- 批准号:82304600
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Molecular Mechanism of long Noncoding RNAs in Phenylketonuria
长非编码RNA在苯丙酮尿症中的分子机制
- 批准号:
10562363 - 财政年份:2023
- 资助金额:
$ 68.48万 - 项目类别:
Using microfluidics to realize patient-specific anti-cancer immunotherapies
利用微流控实现患者特异性抗癌免疫疗法
- 批准号:
10702214 - 财政年份:2023
- 资助金额:
$ 68.48万 - 项目类别:
Investigating the effects of APOE and APOE-related AD risk genes on human microglia activity and lipid metabolism in aging and disease
研究 APOE 和 APOE 相关 AD 风险基因对衰老和疾病过程中人类小胶质细胞活性和脂质代谢的影响
- 批准号:
10900992 - 财政年份:2023
- 资助金额:
$ 68.48万 - 项目类别:
Exploring the role of ER Beta in disease penetrance in individuals with Li-Fraumeni syndrome
探索 ER Beta 在 Li-Fraumeni 综合征个体疾病外显率中的作用
- 批准号:
10548896 - 财政年份:2022
- 资助金额:
$ 68.48万 - 项目类别: